Executive Summary
=================

1. The issue
------------

Diabetes has become the main cause of end-stage renal disease. 30% to 40% of all type 1 and type 2 diabetic patients develop a diabetic nephropathy. The costs for the treatment of diabetic patients with end-stage renal disease have been rising in the last years and have become a relevant economic topic of the health service.

Diabetic nephropathy is diagnosed by clinical aspects. Patients suffering from diabetes mellitus for several years, diabetic retinopathy, and proteinuria are defined as patients with diabetic nephropathy. However, valid data for this definition are missing for type 2 diabetes.

The earliest clinical predictor of nephropathy is the appearance of low abnormal levels of albumin in the urine, known as microalbuminuria. This is the reason for developing tests for microalbuminuria.

2. Objectives
-------------

What significance does the determination of albuminuria have on the precaution and course-control of the diabetic nephropathy?a) in type 1 diabetic patientsb) in type 2 diabetic patientsWhich is an appropriate time to determine the albuminuria for the purpose of precaution and course-control of the diabetic nephropathy?a) in type 1 diabetic patientsb) in type 2 diabetic patientsWhich method of testing is most effective concerning economic and medical aspects?

3. Methods
----------

Published literature from 1998 up to 2004 was identified by searching in the following databases: PSYCINFO, PSYNDEX, EMBASE, EMBASE Alert, Int. Health Technology Assessment, MEDLINE, MEDLINE ALERT, SCISEARCH, SOCIAL SCISEARCH, GEROLIT, Heclinet, AMED, Biosis Prev AB, Biotechnobase, Elsevier Biobase, Eth-med, Euroethics, SOMED, DARE, NEED, INAHTA, and Cochrane Library. Most of the guidelines were found by hand searching in the internet.

4. Results and discussion
-------------------------

Of 2,792 citation titles and abstracts examined, 274 articles were retrieved for full-text review. Five metaanalyses and reviews, one review about clearing of guidelines (regarding 18 international guidelines) and four guidelines met the inclusion criteria for screening for microalbuminuria and type 1 diabetes. Seven metaanalyses, one HTA report, one review about clearing of guidelines (regarding 17 international guidelines), and seven guidelines met the inclusion criteria for screening for microalbuminuria and type 2 diabetes.

The methodological quality of the articles varied but was on average level. Most of these trials were cross-sectional and cohort studies. Almost each guideline recommends a screening for microalbuminuria every year. Type 1 diabetic patients should start the screening five years after diagnosis of diabetes. Different recommendations exist with regard to the screening for microalbuminuria in young type 1 diabetic patients, especially in puberty.

Microalbuminuric type 1 and type 2 patients should be screened every three to six months.

Most of these recommendations are only based on expert consensus. There are no randomised controlled trials which proof the recommendations.

Sensitivity and specificity of microalbuminuria are high in type 1 diabetes, whereas in type 2 diabetes sensitivity of the microalbuminuria is high but specificity is only moderate. As the test will be incorrectly positive in many type 2 diabetic patients, these patients suffer the threatening of dialysis. In addition, there is no real consequence of a positive test result regarding the therapy of the diabetic nephropathy. The only proofed therapy is to achieve strictly normal values of glycosylated hemoglobin (HbA1c) and a normal blood pressure (\<120/80 mm Hg).

5. Conclusion
-------------

Most guidelines recommend an albumin screening every year, but these recommendations are only based on expert consensus.

The specificity of this screening is rather low.

False positive tests in type 2 diabetic patients cause psychological problems.

The consequence of a positive test leads to the recommendation to achieve a \"normal blood pressure\" and a \"normoglycaemia\" - but this applies to each diabetic patient.

Based on these facts, the screening for albuminuria in type 1 or type 2 diabetes patients cannot be recommended.

Without the evidence of the benefit, this screening cannot be economic.

In order to prove a benefit of this screening, large, clinical, controlled trials are necessary.
